Adventrex Pharmaceuticals nach dem Re-Split - 500 Beiträge pro Seite

[Tommi33]

Hallo zusammen,

da sich nach dem Resplit WKN und ISIN geändert haben eröffne ich mal nen neuen Thread zu Adventrex Pharmaceuticals. News und Diskussionen sind hier gern gesehen, sinnleere Postings ohne Quellenangabe bzw. fundierte Fakten nicht.

Hier schon mal die neuste News:

ADVENTRX to Resubmit ANX-530 NDA in the Fourth Quarter of 2010



SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, based on information received from the U.S. Food and Drug Administration (FDA), the Company plans to resubmit its New Drug Application (NDA) for ANX-530 (vinorelbine injectable emulsion), or Exelbine™, in the fourth quarter of 2010.

"We are pleased to have clarified with the FDA certain matters concerning the stability data necessary to file the Exelbine NDA," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "The studies that will generate the stability data from our intended commercial manufacturing site that the FDA wishes to see are ongoing, and we plan to resubmit the NDA in the fourth quarter of this year."

ADVENTRX submitted an NDA for ANX-530 to the FDA in December 2009. The Company announced on March 1, 2010 that it had received a refusal-to-file letter from the FDA regarding that submission. In the letter, the FDA indicated that the data included in the December 2009 NDA submission from the intended commercial manufacturing site was insufficient to support a commercially-viable expiration dating period. The FDA identified only this one chemistry, manufacturing and controls (CMC) reason for the refusal to file. No clinical or nonclinical issues were identified.

LG Tommi

[sawasdeekhrab]

hallo allerseits.
also die news sind nicht gut-hier ist sehr viel geduld und zeit angesagt,denn vor ende 3.anfang 4.q wird sich nicht viel tun.
der kurs wie schon vermutet faellt wie in stein und wird bestimmt noch unter 3 dollar gehen.
alles in allem nicht gerade rosige aussichten.
kann von euch schon jemand in usa handeln???
ich nicht-order wird bei mir abgewiesen.
,
mfg sawasdee

[kunokuhn]

Antwort auf Beitrag Nr.: 39.409.877 von sawasdeekhrab am 27.04.10 16:52:32

nix mehr los hier

[Tommi33]

Antwort auf Beitrag Nr.: 39.443.335 von kunokuhn am 03.05.10 10:49:00

Alle warten ab was passiert, und solange keine News kommen passiert halt nix. Oder wolltest lieber ein Rumgestänker wie bei WamMu haben ?

LG Tommi

[Expertchen007]

uihh heftig rund 50 % seit Splitt minus.... das sind mal wieder so Sachen...bin nicht investiert..aber ist heftig

[dottore]

Antwort auf Beitrag Nr.: 39.447.737 von Expertchen007 am 03.05.10 20:27:39

wann würdest du investieren? Bei welchem Kurs und zu welchem Zeitpunkt?

Warum? Danke

[Expertchen007]

Antwort auf Beitrag Nr.: 39.455.073 von dottore am 04.05.10 18:54:00

wann würdest du investieren? Bei welchem Kurs und zu welchem Zeitpunkt?

Hier momentan gar nicht...die Erfahrung sagt nach Splitt wird der Kurs nicht besser..sehe keinen Grund auf dem Level was zu machen...bin eh stark in Antisoma drin..die steht fest wie eine Eiche in diesen Tagen ( noch ).

Der Markt wird für weitere Korrekturen sorgen..und das nicht wenig......

Schade für die jenigen die gehalten haben ..denn nun würde der Kurs vor Splitt bei 2,35 :25 = 0,093 € stehen..das ist verdammt wenig

[Expertchen007]

Wird ja immer negativer

1,77 € = 0,071 € vor Splitt

[kunokuhn]

Antwort auf Beitrag Nr.: 39.492.764 von Expertchen007 am 10.05.10 16:00:32

schade
sitze auf heftigen verlustren

[Tommi33]

Antwort auf Beitrag Nr.: 39.494.136 von kunokuhn am 10.05.10 18:45:57

Dann hast du nur 2 Möglichkeiten entweder Verluste realisieren und mit Gewinnen woanders verrechnen lassen oder aussitzen und hoffen das sie sich fangen und wieder hoch kommen.

Meine persönliche Strategie ist verbilligen und aussitzen, vielleicht kommt ja doch nochmal ne Wende zum Guten und wenn nicht Pech gehabt.

LG Tommi

[Tommi33]

ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on May 17

SAN DIEGO, May 10, 2010 /PRNewswire via COMTEX/ --ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, May 17, 2010, at 11:05 a.m. local time (6:05 a.m. Eastern time), in the Albemarle Suite at the Grosvenor House Hotel in London.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals Web site at www.adventrx.com. An archived presentation will be available on the Web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's Web site at www.adventrx.com.

SOURCE ADVENTRX Pharmaceuticals, Inc.

Quelle:
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

LG Tommi

[dottore]

heute gab es einen Ruck nach oben, gleich 12 %. Gerade deshalb und trotzdem bin ich endlich dabei.
Einstieg zu 2,58 $

Denke, das ist der Wendepunkt, auch wenn ich lieber 10 Cent früher eingestiegen wäre.

[dottore]

Antwort auf Beitrag Nr.: 39.502.373 von dottore am 11.05.10 19:34:45

ja, das war vorher. Jetzt bei 1,90 $ bin ich dick im Minus und überlege, ob ich verbilligen sollte.

[somami2006]

Antwort auf Beitrag Nr.: 39.668.842 von dottore am 11.06.10 12:37:52

und hast du verbilligt??????

[dottore]

Antwort auf Beitrag Nr.: 39.681.384 von somami2006 am 15.06.10 04:00:26

immer noch nicht, aber ich werde es noch tun

[Expertchen007]

oh weh ihr armen Altaktionäre......1,49 € : 25 = 0,06 € ........böser Abschlag seit R/S......wenn ich mir erinnere war letzer Kurs vor am R/S Tag....0,18 €

Davor gings ja schon heftig runter ......musste mal reinschauen...weil es auch bei GENTA einen neuen RS gibt - allerdings mit 1 :100.......Adventrex war eine gute Erfahrung diesbezüglich wie es laufen kann ( bin nicht drin und war nicht drin - zum Glück )

[dottore]

Antwort auf Beitrag Nr.: 39.689.866 von Expertchen007 am 16.06.10 11:43:52

immerhin,
habe den Absturz nach dem Resplit abgewartet. Beim ersten Zeichen einer Bodenbildung, bei 2,40 bin ich rein mit einer ersten Position, dann kam die Unruhe an den Märkten und hat auch diesen Wert runter gezogen. Der Chart sieht dadurch nicht mehr gut aus. Ich kann mir vorstellen, dass es noch bis 1,70 $ runter geht. Das wäre der Punkt (ungefähr) wo ich nachkaufe. ...

[dottore]

ich habe immer noch nicht nachgekauft. Bei 1,30 - 1,40 habe ich es verpasst und jetzt lohnt sich das nicht wirklich.
Wann und ob wieder ein rasanter Anstieg kommt? Vielleicht schaff ich es ja doch noch zu verbilligen...?

[osterhary]

Antwort auf Beitrag Nr.: 39.891.632 von dottore am 28.07.10 18:24:27

Hallo noch jemand da - die Perle erwacht gerade wieder.

ADVENTRX Arzneimittel Erhalten Benachrichtigung der Erlaubnis für Offene Ansprüche auf Exelbine (TM) (ANX-530)

SAN DIEGO, am 6. Okt 2010/PRNewswire über COMTEX/-

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…


ADVENTRX Pharmaceuticals, Inc (NYSE Amex: ANX) heute gab bekannt, dass er eine Benachrichtigung der Erlaubnis vom amerikanischen Patent- und Handelsmarke-Büro (USPTO) für seine amerikanische offene Anwendung betitelt "Zusammensetzungen erhalten hat, um Hoch Auflösbare Wasserrauschgifte Zu liefern." Die offenen Ansprüche werden zu Formulierungen von vinorelbine bitartrate geleitet und stellen Schutz für den Leitungsproduktkandidaten der Gesellschaft, ANX-530 (vinorelbine injectable Emulsion), oder Exelbine (TM) zur Verfügung. Die Benachrichtigung der Erlaubnis ist die offizielle Kommunikation des USPTO, dass die Überprüfung der offenen Anwendung erfolgreich vollendet worden ist, und dass, auf die rechtzeitige Zahlung von anwendbaren Gebühren, ein Patent ausgegeben wird. Einmal ausgegeben, bevor es offene Begriff-Erweiterung in Betracht zieht, wird das Patent Einschluss für Exelbine bis Juli 2024 zur Verfügung stellen.

"Die Benachrichtigung der Erlaubnis ist ein positiver Schritt zur zukünftigen Kommerzialisierung von Exelbine, und wir müssen auf der Spur einen Neuen Rauschgift-Antrag für Exelbine dieses Viertel einreichen," setzte Brian M. Culley, Geschäftsführer von ADVENTRX fest.

[kunokuhn]

Antwort auf Beitrag Nr.: 40.276.414 von osterhary am 06.10.10 18:36:14

die Hoffnung stirbt zuletzt
habe meine Teile noch
muss natürlich ganz schön steigen
um Pari auszusteigen

[osterhary]

Sehr gute news heute. Leider niemand mehr da. Aber ab morgen wieder, davon bin ich überzeugt.

[kunokuhn]

Antwort auf Beitrag Nr.: 40.445.094 von osterhary am 03.11.10 14:33:55

bin noch da

[kunokuhn]

Antwort auf Beitrag Nr.: 40.445.094 von osterhary am 03.11.10 14:33:55

springt nicht an das Teil

[kunokuhn]

Antwort auf Beitrag Nr.: 40.445.094 von osterhary am 03.11.10 14:33:55

was ist denn heute los

[yaman]

Antwort auf Beitrag Nr.: 40.644.657 von kunokuhn am 03.12.10 21:16:02

Erstaunlich. Gibt es Nachrichten, Ergebnisse o.ä.?

Erste ordentliche Gegenbewegung seit dem Split. Mal sehen, wie weit das geht.

[dottore]

Antwort auf Beitrag Nr.: 39.891.632 von dottore am 28.07.10 18:24:27

nein, ich habe es nicht mehr geschafft zu verbilligen!

Habe mich letzte Woche leider für einen anderen Wert entschieden, der aus meiner Sicht langfristig interessanter ist und bei dem ich in den nächsten Monaten einen Hype erwarte.

Ich meine Maxygen. Einstieg 6,68 $

[dottore]

immerhin nicht mehr im Minus ....

[kunokuhn]

Antwort auf Beitrag Nr.: 40.657.072 von dottore am 06.12.10 20:17:20

nix los hier

[yaman]

und wieder 10% up.

[Tommi33]

Das liest sich doch schon ganz gut:

ADVENTRX Requests Meeting with FDA to Discuss ANX-514 Study

SAN DIEGO, Dec. 15, 2010 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) to schedule a meeting for the purpose of discussing its product candidate ANX-514 (docetaxel emulsion for injection). The FDA is expected to set the meeting date within 60 days of receiving the request from ADVENTRX.

"We have performed an extensive analysis of the data from our bioequivalence study of ANX-514, as well as on results from other trials using Taxotere(R), and plan to discuss our findings at the meeting," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

"Based in part on the substantial variability observed with Taxotere as reported in the literature, we believe the transitory elevations in total docetaxel concentrations for ANX-514 do not affect adversely its safety or efficacy relative to Taxotere. However, the FDA is the final arbiter of safety and efficacy and, following our meeting, we will provide an update on the next steps and requirements for advancing ANX514 toward an NDA submission," Mr. Culley continued.

Gefunden hier -> http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

60 Tage ab 15.12. dann wäre ja ungefähr Mitte Februar mit Ergebnissen zu rechnen.

LG Tommi

[Tommi33]

Und das hab ich grad noch gefunden:

Adventrx Pharmaceuticals(ANX_)

Drug/indication: ANX-530 for non-small cell lung cancer

Approval decision date: May 3, 2011 (estimated, based on Adventrx's Nov. 3, 2010 filing and assuming a six-month FDA review.)

ANX-530 is a reformulation of the generic chemotherapy drug vinorelbine. The FDA issue a refuse-to-file letter for ANX-530 in 2010.

http://www.thestreet.com/story/10944267/2/biotech-calendar-f…

Tommi

[kunokuhn]

Antwort auf Beitrag Nr.: 40.730.782 von Tommi33 am 17.12.10 19:49:35

was steht denn da drinn
kann nicht so gut englisch

[Tommi33]

Antwort auf Beitrag Nr.: 40.733.088 von kunokuhn am 18.12.10 16:30:39

Welches von beiden meinst denn ? Und eigentlich reicht es den Text durch Google zu jagen um alles zu verstehen.

Also im ersten steht das im Mai Ergebnisse von ANX-530 erwartet werden und im 2ten das in 60 Tagen mit einer Antwort von der FDA zu ANX-514 gerechnet wird. So verstehe ich es zumindest, falls ich mich irre bitte ich um Korrektur.

LG Tommi

[kunokuhn]

Antwort auf Beitrag Nr.: 40.733.119 von Tommi33 am 18.12.10 16:44:47

was ist denn heute los

[Tommi33]

Zitat von kunokuhn: was ist denn heute los

Du kannst immer Fragen fragen da schlackern einem die Ohren

Sag du mir was heute bei Xoma los war, dann verrat ich dir eventuell was hier los war

Nicht das ich mich nicht freuen würde aber Anstieg ist für mich Anstieg und den geniess ich ich ob ich weiss warum oder net ist mir dabei so ziemlich Wurst, Hauptsache GRÜN !!

Bis die Tage
Tommi

[kunokuhn]

Antwort auf Beitrag Nr.: 40.747.065 von Tommi33 am 21.12.10 21:01:24

bei Xoma weis net
hier is OK
konnte leider nix nachkaufen

[Tommi33]

Antwort auf Beitrag Nr.: 40.747.120 von kunokuhn am 21.12.10 21:11:04

Tja ist immer so eine Sache mit dem Nachkaufen, setzt du auf nen totes Pferd ist ratz fatz die gesamte Kohle weg und grad bei Biotech kann das ganz schnell gehen. Kiri hat bei Xoma grad ne News aufgetan aber ob das der Grund für den Anstieg ist weiss ich auch nicht, weil das ist alles schon lange bekannt. Ich bleibe in beiden drin, sinds tote Pferde ist die Kohle eh weg und jetzt umschichten um hier oder da zu verbilligen wäre ungefähr so als ob man aus ner 75:25 Chance rausgeht und ins Kasino auf Schwar oder Rot setzt.

LG Tommi

P.S. Und hinterherrennen ist nie gut, wenn du noch was suchst im Bereich Biotech -> Arena, Clinuvel, Antisoma oder hier mal schauen -> http://www.thestreet.com/story/10944267/1/biotech-calendar-f…

Aber alles ohne Gewähr !!

[Tommi33]

ADVENTRX Pharmaceuticals to Present at the 4TH Annual OneMedForum Business Development and Investment Conference on January 11

SAN DIEGO, Jan. 4, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 4th Annual OneMedForum Business Development and Investment Conference on Tuesday January 11, 2011 at 10:00 a.m. Pacific time, in the Renaissance room at the Sir Francis Drake Hotel in San Francisco, CA.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

SOURCE ADVENTRX Pharmaceuticals, Inc.

[teich61]

Big New´s !!!!

FDA Accepts Exelbine NDA for Filing





Press Release Source: ADVENTRX Pharmaceuticals, Inc. On Thursday January 6, 2011, 8:00 am
SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for its product candidate ANX-530 (vinorelbine injectable emulsion), or Exelbine. The filing of the Exelbine NDA means the FDA has made a threshold determination that it is sufficiently complete to permit a substantive review.

"We are pleased to have reached this important milestone, and look forward to working with the FDA on moving Exelbine toward approval in 2011," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

About Exelbine

ADVENTRX is seeking approval of Exelbine for the same indications as Navelbine®, a branded formulation of vinorelbine, including non-small cell lung cancer. ADVENTRX submitted the NDA as a 505(b)(2) application that relies in part on the FDA's findings of safety and effectiveness of a reference drug. The Exelbine NDA includes data from one clinical bioequivalence study designed to assess the pharmacokinetic equivalence of Exelbine and Navelbine, the reference drug. In this clinical bioequivalence study, Exelbine and the reference drug were determined by ADVENTRX to be bioequivalent.

ADVENTRX retains exclusive worldwide rights to Exelbine, other than in South Korea, China, Hong Kong, Macau and Taiwan. In March 2010, the FDA conditionally accepted "Exelbine" as the proposed proprietary name for ANX-530. The United States Patent and Trademark Office has allowed patent claims related to Exelbine, which claims will issue in January 2011 and expire in November 2027.


mfg teich

[osterhary]

Antwort auf Beitrag Nr.: 40.811.045 von teich61 am 06.01.11 14:26:42

Herzlichen Glückwunsch die durchgehalten haben.
FDA für Exelbine ist durch. Die Rakete kann starten.
http://www.finanznachrichten.de/nachrichten-aktien/adventrx-…

[Tommi33]

Antwort auf Beitrag Nr.: 40.811.386 von osterhary am 06.01.11 14:58:16

Und schon fängt die Rakete an zu stottern:

ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million

SAN DIEGO, Jan. 7, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has entered into definitive agreements to sell 8,184,556 units in a registered direct offering to RA Capital Management, certain healthcare-focused investors, and other institutional investors for a per unit purchase price of $2.75, representing gross proceeds to ADVENTRX of approximately $22.5 million. Each unit consists of one share of common stock, a Series A warrant and a Series B warrant. ADVENTRX plans to use the net proceeds from the offering to fund activities relating to acquiring and developing additional products or product candidates, to continue development of its current lead product candidates, and for general corporate purposes.

The Series A warrants are exercisable for up to an aggregate of 2,046,139 shares of ADVENTRX's common stock. The Series A warrants will have an exercise price of $2.75 per share and will be exercisable at any time after the closing of the transaction and before the date that is 5 trading days after the 1-year anniversary of the initial exercise date. The Series B warrants are exercisable for up to an aggregate of 2,046,139 shares of ADVENTRX's common stock. The Series B warrants also will have an exercise price of $2.75 per share and will be exercisable at any time after the closing of the transaction and before the 5-year anniversary of the initial exercise date. The closing of the offering is expected to take place on or about January 11, 2011, subject to the satisfaction of customary closing conditions.

Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NasdaqGM: RODM), acted as the exclusive placement agent for the transaction.

The securities described above are being offered by ADVENTRX pursuant to an effective registration statement(s) on Form S-3 filed with the Securities and Exchange Commission ("SEC"). A prospectus supplement relating to the offering will be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained from the SEC's website at www.sec.gov or directly from Rodman & Renshaw, LLC by request to [e-mail] or [phone].

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

[Tommi33]

ADVENTRX Announces Signing of Term Sheet for Acquisition of Poloxamer-Based Therapeutics

-- Current discussions contemplate:
- All-stock transaction (assuming stockholder approval)
- Over 92% of merger consideration based on milestone achievement
- Over 70% of merger consideration based on NDA acceptance/approval

SAN DIEGO, Jan. 7, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has signed a term sheet to acquire a private company that holds certain rights and know-how to poloxamer-based therapeutics. The term sheet is non-binding on both ADVENTRX and the target company.

About the Potential Transaction

Current discussions with the target company contemplate an all-stock acquisition by merger. Other than an upfront issuance of approximately 19% of ADVENTRX's currently outstanding common stock (of which only 6.5% would be fully-vested upon issuance and 12.5% would vest subject to successfully attaining the initial development milestone), the acquisition consideration would be issued based on the target company's lead product candidate, or the TPC, successfully attaining development milestones, such as first patient dosing in a pivotal trial, acceptance by the FDA of a New Drug Application, or NDA, for the TPC and NDA approval.

Based on current discussions, of the total acquisition consideration that could be paid, approximately 71% is tied to NDA acceptance and NDA approval. If all development milestones are achieved, including NDA approval, stockholders of the target company would own approximately 47% of ADVENTRX (based on ADVENTRX's currently outstanding shares of common stock but including the shares issued to the target company's stockholders).

If ADVENTRX's stockholders do not approve the issuance of shares beyond the upfront issuance as required by NYSE Amex listing standards, ADVENTRX expects to pay the target company's stockholders in cash the value of the shares it otherwise would have issued in excess of the 19% upfront issuance described above, with the NDA acceptance and NDA approval milestone payments payable based on net sales of the TPC and all milestone payments payable in quarterly installments.

The target company has no employees, but in connection with a transaction ADVENTRX expects to retain the services of certain members of the target company's management team who have been involved in the development of the TPC.

About the Planned Development of the Target Company's Lead Product Candidate

If a transaction is consummated, ADVENTRX expects to conduct a phase 3 clinical trial of the TPC for the treatment of sickle cell crisis. Prior to initiating this study, ADVENTRX would discuss the design and analytical methodologies of the study with the FDA. Based on its evaluation to-date, ADVENTRX believes the out-of-pocket cost to submit an NDA covering the TPC would be approximately $15 million to $25 million over 3 years. ADVENTRX expects to agree to commit approximately $1.5 million to conduct particular activities during the first 12 months following consummation of the acquisition. The principal source of market exclusivity for the TPC for the sickle cell disease indication is expected to be based on orphan drug exclusivity. The FDA has granted an orphan drug designation for the TPC for the treatment of sickle cell crisis.

The foregoing is based on ADVENTRX's current discussions with the target company. There is no guarantee that definitive agreements will be entered into or that ADVENTRX will consummate a transaction with the target company or that any transaction ADVENTRX ultimately may consummate will be on the terms described above.

About the Target Company's Lead Product Candidate

The TPC is a purified form of a nonionic block copolymer surfactant that is believed to adhere to hydrophobic surfaces that develop when cells are damaged. The TPC is designed to restore hydration lattices and minimize the cascade of adhesive, inflammatory and coagulation responses that cause adhesion of cells, impaired blood flow and tissue ischemia. Improving blood flow in the microvasculature may benefit patients with sickle cell disease in acute crisis, which is associated with microvascular occlusion. A phase 3 study in this indication previously was initiated by a prior sponsor of the TPC, but was discontinued primarily due to inadequate capital being available to continue.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are being developed to improve the performance of existing anti-cancer drugs by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

[wave1984]

die Aktie hier ist mit die größte verarsche überhaupt

[Tommi33]

Antwort auf Beitrag Nr.: 40.851.071 von wave1984 am 12.01.11 21:27:23

Dann haste Genta noch nicht gesehen.

LG Tommi

[Tommi33]

ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing

SAN DIEGO, Jan. 13, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has completed the previously announced sales of 8,184,556 units in a registered direct offering to RA Capital Management, certain healthcare-focused investors, and other institutional investors for a per unit purchase price of $2.75, representing gross proceeds to ADVENTRX of approximately $22.5 million. Each unit consists of one share of common stock, a Series A warrant and a Series B warrant. ADVENTRX plans to use the net proceeds from the offering to fund activities relating to acquiring and developing additional products or product candidates, to continue development of its current lead product candidates, and for general corporate purposes.

The Series A warrants are exercisable for up to an aggregate of 2,046,139 shares of ADVENTRX's common stock. The Series A warrants have an exercise price of $2.75 per share and are exercisable at any time after the closing of the transaction and before the date that is 5 trading days after the 1-year anniversary of the initial exercise date. The Series B warrants are exercisable for up to an aggregate of 2,046,139 shares of ADVENTRX's common stock. The Series B warrants also have an exercise price of $2.75 per share and are exercisable at any time after the closing of the transaction and before the 5-year anniversary of the initial exercise date.

Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM), acted as the exclusive placement agent for the transaction.

The securities described above are being offered by ADVENTRX pursuant to an effective registration statement on Form S-3 filed with the Securities and Exchange Commission ("SEC"). A prospectus supplement relating to the offering was filed with the SEC on January 7, 2011.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus can be obtained from the SEC's website at www.sec.gov or directly from Rodman & Renshaw, LLC by request to [e-mail] or [phone].

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[Tommi33]

ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine(TM) NDA

SAN DIEGO, Jan. 19, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011 for the review of the Exelbine (ANX-530) New Drug Application (NDA). The acceptance of the Exelbine NDA is the FDA's determination that the application is sufficiently complete to permit a substantive review, and the PDUFA date is the goal date for the FDA to complete its review of the NDA.

"With a September PDUFA date established in the Day 74 letter from the FDA, we look forward to working closely with the Agency on moving Exelbine toward approval this year," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[dottore]

Antwort auf Beitrag Nr.: 40.888.538 von Tommi33 am 19.01.11 14:59:30

das sollte heute gut hochgehen, vorbörslich schon 200 Tausend Stückt mit 10 Cent Aufschlag gehandelt

[Tommi33]

ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15

SAN DIEGO, Feb. 10, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE AMEX: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 13th Annual BIOCEO & Investor Conference on Tuesday February 15th, at 1:30pm. Eastern time, in the Conrad Salon at the Waldorf Astoria Hotel in New York.

Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at www.adventrx.com. An archived presentation will be available on the web site for 30 days.

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[Tommi33]

ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
Company to Hold Conference Call Monday, February 14th at 8:30am Eastern Time

SAN DIEGO, Feb. 12, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it will hold a conference call on Monday, February 14th, 2011 at 8:30am Eastern Time to provide an update regarding its pipeline expansion efforts.

Interested parties may access the conference call by dialing [phone] from the U.S. and [phone] from outside the U.S. and should request the ADVENTRX Pharmaceuticals Corporate Update Call. The webcast will be available live via the Internet by accessing the Investors section of ADVENTRX's website at http://ir.adventrx.com. Replays of the webcast will be available on the Company's website for 30 days and a phone replay will be available through February 19th, 2011 by dialing [phone] from the U.S. and [phone] from outside the U.S. and entering conference reference number 448547.

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[Tommi33]

ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.

-- All-stock transaction (assuming stockholder approval)
-- Over 95% of merger consideration based on milestone achievement
-- Over 75% of merger consideration based on NDA acceptance/approval
-- Conference call to discuss pending acquisition today at 8:30 am ET

SAN DIEGO, Feb. 14, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it has entered into a definitive agreement to acquire SynthRx, Inc. (SynthRx), a private biotechnology company developing a purified form of a rheologic and antithrombotic agent, poloxamer 188 (188).

"The acquisition of SynthRx will be a transformative event for ADVENTRX, adding another late-stage asset to our pipeline," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "The all-stock, milestone-based deal structure is a win for ADVENTRX and its stockholders in that it allows us to retain our cash for development activities and, other than a modest upfront equity payment, ensures we pay only as the 188 program achieves success. I'm pleased that we would have the data from the planned phase 3 study in-hand while having paid less than 25% of the total deal consideration."

"The 188 program will fit well with our existing assets and provide several exciting development opportunities. We would plan to meet with the FDA later this year to reach agreement on a protocol for a pivotal phase 3 study for the treatment of sickle cell crisis in a pediatric population, for which 188 has orphan drug designation. Sickle cell patients are an under-served population suffering from an excruciatingly painful condition with limited palliative options. Beyond sickle cell, we believe 188 has clinical benefits in other acute events related to microvascular-flow abnormalities, such as heart attack, stroke and hemorrhagic shock," Mr. Culley continued.

Under the terms of the all-stock transaction, SynthRx would become a wholly-owned subsidiary of ADVENTRX in exchange for shares of ADVENTRX common stock representing, in the aggregate, an approximately 4% ownership stake in ADVENTRX. SynthRx stakeholders also would be entitled to receive additional shares of common stock upon successful achievement of development milestones consisting of dosing the first patient in a phase 3 clinical study, acceptance by the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) and approval by the FDA of an NDA. If all milestones are achieved without reduction, the number of shares issued in connection with the acquisition would, in the aggregate, represent an approximately 40% ownership stake in ADVENTRX (based on currently outstanding shares plus shares issued in connection with the acquisition). Of the total number of shares issuable, more than 75% are based on NDA acceptance and approval.

If ADVENTRX's stockholders do not approve the issuance of the milestone-related shares as required by NYSE Amex listing standards, ADVENTRX expects to pay SynthRx's stakeholders in cash the value of the shares it otherwise would have issued, with the NDA acceptance and NDA approval milestone payments payable based on net sales of 188 and all milestone payments payable in quarterly installments.

About Poloxamer 188

Poloxamer 188 is a nonionic block copolymer surfactant that is believed to adhere to hydrophobic surfaces that develop when cells are damaged. It has been shown to restore hydration lattices and minimize the cascade of adhesive, inflammatory and coagulation responses that cause adhesion of cells, impaired blood flow and tissue ischemia. Improving blood flow in the microvasculature may benefit patients with sickle cell disease in acute crisis, which is associated with microvascular occlusion. Formulations of 188 have been extensively studied in numerous clinical trials, including a 2,950-patient, randomized, controlled study in acute myocardial infarction.

SynthRx's lead product candidate, a purified form of poloxamer 188, is an investigational product intended to treat micro-vascular disorders. Purified poloxamer 188 has been evaluated in multiple clinical studies, including a 255-patient, randomized, double-blind, placebo-controlled phase 3 study in patients with sickle cell disease in acute vaso-occlusive crisis. The FDA has granted orphan drug designation for poloxamer 188 for the treatment of sickle cell crisis.

About Sickle Cell Disease and Sickle Cell Crisis

Sickle cell disease (SCD) or sickle cell anemia (SCA) is a genetic, autosomal, recessive blood disorder characterized by red blood cells that assume an abnormal, rigid, sickle shape. This sickling is caused by an abnormality in the hemoglobin molecule found in red blood cells which carry oxygen throughout the body. Sickled red blood cells cannot pass through capillaries and may occlude capillaries and small blood vessels. This blockage can cause a wide range of serious and life-threatening conditions, including chronic hemolytic anemia, chronic pain and acute painful crisis, stroke, acute chest syndrome, as well as cumulative damage to tissues and organs.

Patients with SCD experience an average life expectancy of approximately 40 years. According to the National Institutes of Health (NIH) and the Sickle Cell Disease Association of America (SCDAA), it is estimated that over 70,000 people have sickle cell disease and about 1,000 babies are born with the disease each year in the United States.

Vaso-occlusive crisis is caused by sickle-shaped red blood cells that obstruct capillaries and restrict blood flow to an organ, resulting in ischemia (restriction of blood supply), pain, necrosis, and often organ damage. The frequency, severity, and duration of these crises can vary considerably.

Conference Call Information

ADVENTRX will hold a conference call today at 8:30 am ET to discuss the potential acquisition. Interested parties may access the conference call by dialing [phone] from the U.S. and [phone] from outside the U.S. and requesting the ADVENTRX Pharmaceuticals Corporate Update Call. The webcast will be available live via the Internet by accessing the Investors section of ADVENTRX's website at http://ir.adventrx.com. Replays of the webcast will be available on the Company's website for 30 days and a phone replay will be available through February 19, 2011 by dialing [phone] from the U.S. and [phone] from outside the U.S. and entering conference reference number 448547.

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[Tommi33]

ADVENTRX Pharmaceuticals Provides Update on ANX-514

SAN DIEGO, Feb. 15, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today provided an update on its product candidate, ANX-514, its polysorbate 80-free formulation of docetaxel. The U.S. Food and Drug Administration (FDA) determined that ANX-514 could not be approved based on the findings from the bioequivalence study of ANX-514 (Study 514-01) and that additional development activities would be required for approval. ADVENTRX met with the FDA to discuss required activities.

"We are pleased with the outcome of our discussion with FDA, at which the conceptual design of a single, additional clinical study that could support approval of ANX-514 was discussed. We believe the study requested by the Agency is reasonable, and we are developing a study protocol for submission to the FDA. We will provide a further update after receiving feedback from FDA on the protocol," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

"We have netted over $50 million from financings during the last 18 months and we intend to use this capital to continue to develop ANX-514, to pursue acquisition opportunities, such as our recently-announced agreement to acquire SynthRx, and to prepare for the commercial launch of Exelbine(TM), should it be approved," Mr. Culley continued.

ADVENTRX met with the FDA to discuss ANX-514. Prior to the meeting, ADVENTRX submitted to the FDA a data package based on Study 514-01 and published literature. ADVENTRX believes the data package supports the conclusion that comparable clinical outcomes can be expected following treatment with either ANX-514 or Taxotere(R), despite Study 514-01 not demonstrating bioequivalence, its primary endpoint, using an unscaled bioequivalence methodology. In particular, the data package concludes that unbound docetaxel concentrations better represent the pharmacokinetics of docetaxel and are better predictors of clinical effects and outcomes.

The FDA did not agree that evaluating bioequivalence using unbound docetaxel concentrations was warranted and determined that data from Study 514-01 was not adequate to conclude that the short period of higher exposure to total docetaxel concentrations observed early in the treatment cycle with ANX-514 do not adversely affect the safety or efficacy of ANX-514 relative to Taxotere.

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[dottore]

heute wurde bekannt, dass Docetaxel nicht wie geplant die Approvation der FDA erhalten kann, dass weitere Forschungen erforderlich seien. Daraufhin ist der Kurs massiv eingebrochen bis 1,80 $ und schlagartig wieder zurück nachdem die Meldung zuende gelesen wurde.
Denn da heißt es, man wolle den Ansprüchen der FDA gerecht werden und 1 weitere Studie zur Substanz betreiben. Man sei zuversichtlich zu einem positiven Ergebnis zu kommen.
Außerdem habe man 50 Mio $ cash durch die Kapitalmaßnahmen der letzten 18 Monate und werde die angekündigten Projekte weiter verfolgen, so mit der Übernahme von SynthRx und dem Verkaufsbeginn von Exelbine

[cat108]

Antwort auf Beitrag Nr.: 41.045.902 von dottore am 15.02.11 20:54:14

Was ist denn hier los, die Aktie geht ab und keiner merkts??????

[charlie01]

Antwort auf Beitrag Nr.: 41.774.078 von cat108 am 12.07.11 08:51:39

Doch, aber nur wenige!
Das könnte sich bald ändern, denn:
FDA approval on Sept.1 for ANX-530!!!???

[Tommi33]

Antwort auf Beitrag Nr.: 41.774.078 von cat108 am 12.07.11 08:51:39

Merken schon aber hier ist noch ein Thread wo es ruhig und gesittet zugeht und von daher machen wir da nicht viel Wind drum.

LG Tommi

[kunokuhn]

Antwort auf Beitrag Nr.: 41.777.132 von Tommi33 am 12.07.11 16:21:38

muss bei mir noch ein ganzes Stück Aufwärts gehen
hab vor dem Splitt gekauft und nicht mehr verbilligt

[Tommi33]

Antwort auf Beitrag Nr.: 41.777.811 von kunokuhn am 12.07.11 18:15:19

Also dann hats auf jeden Fall keine Eile wenn du deine Stücke noch hast, ich warte auch schon länger und mach mir da auch gar keinen grossen Kopf drum, sind ja hier nicht bei Genta

LG Tommi

[scorp4ik]

hi,

kenn einer von euch livestream aus den USA für die Aktie?

Dake

[Tommi33]

Antwort auf Beitrag Nr.: 41.782.637 von scorp4ik am 13.07.11 15:52:42

Ich hoffe mal das ich dich jetzt korrekt missverstanden habe und du nen Chart statt nem Stream meintest dann wird dir das hier helfen:

Intraday


Ansonsten wüsst ich nicht was du mit Live Stream meinen könntest.

LG Tommi

[Tommi33]

ADVENTRX Reports Second Quarter 2011 Financial Results

SAN DIEGO, Aug. 8, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the periods ended June 30, 2011.

"As we head into the second half of the year, we are taking steps to prepare for our launch of Exelbine(TM) into the U.S. market, should it be approved on or around FDA's PDUFA goal date of September 1, 2011," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Having a commercial infrastructure will expand our strategic options and increase stockholder value."

"In parallel, we are working to finalize the protocol for a phase 3 pediatric study of ANX-188, our first-in-class treatment for sickle cell crisis, for which FDA has granted orphan drug designation. We plan to initiate this study in 2012. There are no FDA-approved drugs designed to treat patients in crisis, making this an area of significant unmet need," Mr. Culley continued.

"We also are excited about ANX-514, our detergent-free reformulation of the blockbuster drug Taxotere®, which recently went off-patent. We plan to meet with FDA in the next quarter to discuss a single, additional study in which we compare the safety profiles of Taxotere with corticosteroid premedication and ANX-514 without corticosteroid premedication. We believe this single study will provide sufficient clinical data to support a new drug application, should the study demonstrate comparable safety profiles between ANX-514 and Taxotere, and a competitive advantage over Taxotere and other detergent-containing formulations of docetaxel," Mr. Culley concluded.

Second Quarter 2011 Operating Results

ADVENTRX's net loss applicable to common stock for the second quarter of 2011 was $4.4 million, or $0.17 per share, compared to a net loss applicable to common stock of $5.0 million, or $0.39 per share, for the same period in 2010. Included in the net loss applicable to common stock for the second quarter of 2010 was a non-cash, deemed dividend expense of $3.1 million incurred in connection with the Company's May 2010 equity financing.

Research and development (R&D) expenses for the second quarter of 2011 were $1.3 million, an increase of $0.7 million, or 112%, compared to $0.6 million for the same period in 2010. The increase was due primarily to a $0.5 million increase in external nonclinical study fees and expenses and a $0.2 million increase in external bioequivalence and clinical trial fees and expenses. The increase in external nonclinical study fees and expenses resulted primarily from a $0.5 million increase in research-related manufacturing expenses for Exelbine(TM). The increase in external bioequivalence and clinical trial fees and expenses is primarily related to increased clinical trial work of $0.1 million for Exelbine(TM) and clinical consulting expenses of $0.1 million for ANX-188.

Selling, general and administrative (SG&A) expenses for the second quarter of 2011 were $1.8 million, an increase of $0.5 million, or 40%, compared to $1.3 million for the same period in 2010. The increase was due primarily to a $0.2 million increase in personnel costs, mainly due to an accrual for estimated bonus expense related to 2011 performance, and a $0.3 million increase in commercial-readiness activities for Exelbine(TM).

Transaction-related expenses for the second quarter of 2011 were $1.2 million compared to $0 for the same period in 2010. Transaction-related expenses consisted of $1.0 million related to legal, accounting, financial and business development advisory fees associated with the evaluation of potential acquisition targets, including SynthRx, and $0.2 million related to changes in the fair value of contingent consideration related to the SynthRx acquisition.

Year-to-Date Operating Results

ADVENTRX's net loss applicable to common stock for the six months ended June 30, 2011 was $7.3 million, or $0.30 per share, compared to a net loss applicable to common stock of $10.0 million, or $0.86 per share, for the same period in 2010. Included in the net loss applicable to common stock for the six months ended June 30, 2010 was a non-cash, deemed dividend expense of $5.6 million incurred in connection with the Company's January and May 2010 equity financings.

Research and development (R&D) expenses for the six months ended June 30, 2011 were $2.0 million, an increase of $0.1 million, or 4%, compared to $1.9 million for the same period in 2010. The increase was due primarily to a $0.3 million increase in external bioequivalence and clinical trial fees and expenses, a $0.1 million increase in personnel costs, offset by a $0.3 million decrease in external nonclinical study fees and expenses. The increase in external bioequivalence and clinical trial fees and expenses is primarily related to increased clinical trial work of $0.2 million for Exelbine(TM) and clinical consulting expenses of $0.1 million for ANX-188. The decrease in external nonclinical study fees and expenses resulted primarily from a $0.5 million decrease in research-related manufacturing expenses for ANX-514, a $0.4 million decrease in regulatory consulting services for ANX-514, offset by an increase of $0.5 million in research related manufacturing expenses for Exelbine(TM) and an increase of $0.1 million in analytical development expenses for ANX-188.

Selling, general and administrative (SG&A) expenses for the six months ended June 30, 2011 were $3.4 million, an increase of $0.9 million, or 37%, compared to $2.5 million for the same period in 2010. The increase was due primarily to a $0.4 million increase in personnel costs, mainly due to an accrual for estimated bonus expense related to 2011 performance and additional staff hired in 2011, and a $0.5 million increase in commercial-readiness activities for Exelbine(TM).

Transaction-related expenses for the six months ended June 30, 2011 were $2.0 million compared to $0 for the same period in 2010. Transaction-related expenses consisted of $1.8 million related to legal, accounting, financial and business development advisory fees associated with the evaluation of potential acquisition targets, including SynthRx, and $0.2 million related to changes in the fair value of contingent consideration related to the SynthRx acquisition.

Balance Sheet Highlights

As of June 30, 2011, the Company had cash totaling $42.0 million. Stockholders' equity amounted to $46.4 million as of June 30, 2011.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates. The Company's current lead product candidates are Exelbine and ANX-514, novel emulsion formulations of currently marketed chemotherapy drugs, and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis. More information can be found on the Company's web site at

www.adventrx.com

SOURCE ADVENTRX Pharmaceuticals, Inc.

[Tommi33]

ADVENTRX Receives Complete Response Letter for Exelbine NDA
Conference call scheduled for 8:30 a.m. Eastern time Wednesday, August 10

SAN DIEGO, Aug. 9, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the Company's New Drug Application (NDA) for Exelbine(TM) (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer.

The FDA determined that it could not approve the Exelbine NDA in its present form. In particular, the complete response letter noted that, based on inspections at clinical sites, the authenticity of the drug products used in the pivotal bioequivalence trial (Study 530-01) could not be verified, which placed the results of the trial into question. The letter stated that the bioequivalence trial will need to be repeated to address this deficiency.

In addition, the FDA requested information regarding product quality, or CMC matters. All CMC information requests in the complete response letter were the subject of FDA inquiries from earlier in the review cycle, and the Company had submitted responses to each request prior to receipt of the complete response letter.

"We are disappointed with the FDA's determination and, next week, plan to request a type A meeting to discuss its response. Following that meeting, we will be in a better position to comment on the future of our Exelbine program. However, we believe the authenticity of the drug products used in the pivotal study is verifiable and plan to discuss FDA's concerns in this regard. We also will inquire whether FDA has comments to our previously submitted responses," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

"In the meantime, our resources and focus are on ANX-188 and ANX-514, which we believe are the long-term value drivers for our company. Our cash and equivalents of $40.7 million at July 31, plus cost savings from delaying or potentially discontinuing the Exelbine program, will provide us the capital to continue to advance both of these programs," Mr. Culley added.

The Company believes that FDA's concern over drug product authenticity stems from the procedures used to select testing and reserve samples in Study 530-01 and the availability of testing and reserve samples for inspection. The Company believes the procedures used to select testing and reserve samples in Study 530-01 were adequate to verify the authenticity of the drug products. Of note, Exelbine and the reference product come in different package presentations, require different preparation procedures and have different physical characteristics. Based on the different characteristics between the study drugs, the Company believes it is unlikely that study sites would confuse the two study drugs or fail to recognize which drug was being administered to a patient.

Conference Call and Webcast

ADVENTRX will hold a conference call on Wednesday, August 10, 2011 beginning at 8:30 a.m. Eastern time to review the developments discussed in this news release and answer questions. Individuals interested in listening to the conference call may do so by dialing [phone] for domestic callers, [phone] for international callers and requesting the ADVENTRX Pharmaceuticals Update Call, or, from the webcast on the investor relations section of the Company's Web site at www.adventrx.com. A telephone replay will be available for five days approximately one hour after the conclusion of the call by dialing [phone] for domestic callers, or [phone] for international callers, and entering conference number 10003222. The webcast will be available on the Company's Web site for 30 days following the completion of the call.

Das ist erstmal garnicht gut, warten wir mal ab.

LG Tommi

[kunokuhn]

Antwort auf Beitrag Nr.: 41.926.752 von Tommi33 am 10.08.11 05:12:46

warum stehen wir jetzt bei 0,50 €

[yaman]

FDA hat Exelbine abgebügelt.

Dennoch fraglich, ob der Abschlag hier in D ggü. dem Schlußkurs in USA in der Höhe gerechtfertigt ist.

[kunokuhn]

Antwort auf Beitrag Nr.: 41.927.412 von yaman am 10.08.11 09:05:13

in USA ist das Teil doch nach Norden gegangen

[yaman]

ja, aber die news kam erst nach Börsenschluß

http://www.benzinga.com/news/11/08/1846471/adventrx-receives…

[yaman]

ja, aber die news kam erst nach Börsenschluß

http://www.benzinga.com/news/11/08/1846471/adventrx-receives…

[Tommi33]

ADVENTRX Announces Results of FDA Meeting to Discuss Exelbine NDA

SAN DIEGO, Sept. 30, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it held a Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the complete response letter (CRL) it received in August from the FDA regarding the Company's New Drug Application (NDA) for Exelbine(TM) (vinorelbine injectable emulsion) for the treatment of non-small cell lung cancer. During the meeting, ADVENTRX discussed with FDA staff all of the items outlined in the CRL, including responses previously submitted by the Company to the FDA during the NDA review and information the Company believes demonstrates the authenticity of the study drugs used in the pivotal bioequivalence study of Exelbine (Study 530-01).

As previously announced, the CRL stated that the authenticity of the study drugs used in Study 530-01 could not be verified. During the meeting, FDA staff indicated that the clinical sites, which were selected in 2006 by a third-party contract research organization, failed to randomly select and retain reserve samples of the test article (Exelbine) and reference standard (Navelbine®) and this deficiency could not be overcome by alternative methods of verifying authenticity and reiterated that the bioequivalence study would need to be repeated.

Additionally, FDA staff commented that no clinical deficiencies were noted with Study 530-01 and that there were no comments regarding the Company's conclusion that Exelbine and Navelbine are bioequivalent based on Study 530-01 data.

"Although we are pleased with the Agency's assessment of the clinical data, we are disappointed it could not exercise discretion in our case to consider other methods of verifying the authenticity of the study drugs," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "The Agency's assessment of the clinical data gives us confidence that a repeat study would be successful and that Exelbine can be approved. However, although the third-party costs to conduct an additional bioequivalence study and to launch Exelbine are relatively modest, we believe our stockholders are best served by focusing our capital on ANX-188 and ANX-514, which reflect larger market opportunities, and we intend to seek a partner or outside investor for the Exelbine program."

"Our cash and equivalents of $40.7 million at July 31, plus cost savings from discontinuing the Exelbine program, will provide us the capital to advance both our ANX-188 and ANX-514 programs into their respective pivotal clinical studies next year. Additionally, we have taken and will continue to take measures to ensure that our contractors have the qualifications and experience needed to bring new therapies successfully through pivotal studies and make them available to patients," Mr. Culley added.

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[Tommi33]

ADVENTRX and FDA Reach Agreement on Pivotal Study for ANX-514

-- Approved product will not require corticosteroid premedication
-- Single study will support NDA submission as early as 2014

SAN DIEGO, Oct. 26, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it met with the U.S. Food and Drug Administration (FDA) to discuss a single clinical study to support approval of ANX-514 (docetaxel for injectable emulsion), a detergent-free reformulation of Taxotere (docetaxel).

ADVENTRX proposed a non-inferiority study (Study 514-02) with a primary objective of comparing fluid retention following treatment with ANX-514, administered without corticosteroid premedication, and Taxotere®, administered with corticosteroid premedication, which would enroll approximately 400 patients. The FDA agreed that the proposed study would generate sufficient clinical data to support approval of ANX-514 without requiring corticosteroid premedication.

Eric K. Rowinsky, M.D., principal clinical advisor to ADVENTRX, said, "Eliminating the high-dose corticosteroid premedication required with Taxotere would represent a significant benefit to cancer patients. Corticosteroids expose cancer patients to otherwise unnecessary and costly complications, such as hyperglycemia, immunosuppression and insomnia. ANX-514 has the potential to improve the tolerability and safety of docetaxel treatment while eliminating toxicities caused by the polysorbate 80 detergent and complications associated with the Taxotere premedication regimen."

Brian M. Culley, Chief Executive Officer of ADVENTRX, said, "We are very pleased to have reached agreement with the FDA on a reasonable path to approval for ANX-514. Our focus is on initiating Study 514-02 as soon as possible and submitting an NDA in 2014."

Mr. Culley continued: "The high-dose steroids required with Taxotere are problematic for all cancer patients, and in particular those who have diabetes or a predisposition to hyperglycemia, who we estimate constitute one-third of the patients who receive Taxotere."

About Study 514-02

Study 514-02 will be a randomized, open-label, multicenter, non-inferiority study comparing ANX-514, administered without corticosteroid premedication, and Taxotere, administered with corticosteroid premedication, in the treatment of non-small cell lung cancer after failure of prior platinum-based therapy. Approximately 400 patients will be enrolled and treated until evidence of progressive disease, unacceptable toxicity, withdrawal of consent, or other withdrawal criteria are met. The primary objective will be to compare the incidence of fluid retention between study arms. The secondary objectives will be to compare ANX-514 and Taxotere in terms of overall safety profile, objective response rate, duration of response, progression-free survival and overall survival.

http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-newsArti…

[Tommi33]

ADVENTRX Reports Third Quarter 2011 Financial Results

SAN DIEGO, Nov. 7, 2011 /PRNewswire via COMTEX/ --

ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today reported financial results for the third quarter ended September 30, 2011.

"Consistent with our prior guidance, we met with the FDA last month and reached agreement on a single, additional phase 3 study that will support approval of ANX-514 without the high-dose corticosteroid premedication regimen required with Taxotere and other detergent-containing formulations of docetaxel. Also, we have scheduled a meeting with the FDA for later this quarter to discuss ANX-188, our first-in-class treatment for sickle cell crisis, and the design of a phase 3 pediatric study in this indication," stated Brian M. Culley, Chief Executive of ADVENTRX.

"Clarity with the FDA is key to the success of any clinical program. Including the upcoming ANX-188 meeting, we will have met with the FDA four times since September 1, which reflects our commitment to productive dialog with the Agency and the speed at which we are advancing our late-stage programs into their respective phase 3 studies next year," continued Mr. Culley.

Third Quarter 2011 Operating Results

ADVENTRX's net loss applicable to common stock for the third quarter of 2011 was $3.5 million, or $0.13 per share, compared to a net loss applicable to common stock of $1.8 million, or $0.13 per share, for the same period in 2010.

Research and development (R&D) expenses for the third quarter of 2011 were $2.1 million, an increase of $1.2 million, or 123%, compared to $0.9 million for the same period in 2010. The increase was due primarily to a $0.7 million increase in external nonclinical trial fees and expenses, a $0.2 million increase in external clinical trial fees and expenses and a $0.3 million increase in personnel costs. The increase in external nonclinical trial fees and expenses resulted primarily from increased research-related manufacturing expenses of $0.5 million for Exelbine(TM) and $0.2 million for ANX-188. The increase in external clinical trial fees and expenses was primarily related to increased clinical consulting expenses of $0.1 million for ANX-188 and $0.1 million for ANX-514.

Selling, general and administrative (SG&A) expenses for the third quarter of 2011 were $2.0 million, an increase of $1.1 million, or 110%, compared to $0.9 million for the same period in 2010. The increase resulted primarily from a $0.5 million increase in personnel costs, mainly due to additional staff hired in 2011 and an accrual for estimated bonus expense related to 2011 performance, a $0.4 million increase in commercial-readiness activities for Exelbine(TM), and a $0.2 million increase in stock-based compensation.

Transaction-related expenses for the third quarter of 2011 were negative $0.5 million compared to $0 for the same period in 2010. ADVENTRX's remeasurement at September 30, 2011 of the fair values for the contingent asset and contingent liability related to its consideration for the SynthRx acquisition resulted in a net $0.5 million reduction to transaction-related expenses.

Year-to-Date Operating Results

ADVENTRX's net loss applicable to common stock for the nine months ended September 30, 2011 was $10.9 million, or $0.43 per share, compared to a net loss applicable to common stock of $11.8 million, or $0.94 per share, for the same period in 2010. Included in the net loss applicable to common stock for the nine months ended September 30, 2010 was a non-cash, deemed dividend expense of $5.6 million incurred in connection with the Company's January and May 2010 equity financings.

R&D expenses for the nine months ended September 30, 2011 were $4.0 million, an increase of $1.2 million, or 43%, compared to $2.8 million for the same period in 2010. The increase was due primarily to a $0.4 million increase in external clinical trial fees and expenses, a $0.4 million increase in external nonclinical trial fees and expenses and a $0.4 million increase in personnel costs. The increase in external clinical trial fees and expenses was primarily related to increased clinical consulting expenses of $0.2 million for ANX-188 and $0.1 million for ANX-514, as well as a $0.1 million increase for consulting expenses related to Exelbine Study 530-01 clinical site inspections. The increase in external nonclinical trial fees and expenses resulted primarily from increases in research-related manufacturing expenses of $0.8 million for Exelbine and $0.3 million for ANX-188, offset by a $0.7 million decrease in regulatory and research-related manufacturing expenses for ANX-514.

SG&A expenses for the nine months ended September 30, 2011 were $5.4 million, an increase of $2.0 million, or 57%, compared to $3.4 million for the same period in 2010. The increase resulted primarily from a $0.9 million increase in personnel costs, mainly due to additional staff hired in 2011 and an accrual for estimated bonus expense related to 2011 performance, a $0.7 million increase in commercial-readiness activities for Exelbine, a $0.3 million increase in accounting, investor relations and business development professional fees and consulting services and a $0.1 million increase in the cost of ADVENTRX's facilities lease.

Transaction-related expenses for the nine months ended September 30, 2011 were $1.5 million compared to $0 for the same period in 2010. Transaction-related expenses consisted of $1.8 million related to legal, accounting, financial and business development advisory fees associated with the evaluation of potential acquisition targets, including SynthRx, and the execution of the SynthRx acquisition, offset by a $0.3 million reduction related to changes in the fair value of the contingent asset and contingent liability related to its consideration for the SynthRx acquisition.

Balance Sheet Highlights

As of September 30, 2011, the Company had cash, cash equivalents and short-term investments totaling $38.3 million. Stockholders' equity amounted to $43.2 million as of September 30, 2011.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company focused on developing proprietary product candidates. The Company's current lead product candidates are ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis, and ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel. More information can be found on the Company's web site at www.adventrx.com

[sebirem]

aus dem Yahoo US Forum

if they find a partner for Exelbine 28-Dec-11 11:32 am
anx will go to $2.5 in the blink of an eye. If I remember correctly in last earnings report, they said they had dis-continued Exelbine after the lab disaster and said they were actively looking for a partner for it rather than re-start the study. If Exelbine is worth anything near what they say, they should be able to find a partner.

After the last offering, this company has basically fully funded their upcoming trials except for Ex....They have a huge cash position after the last offering---it's over 2x the share price with little or no debt. Someone could buy them for a buck for free and have jet money to get home.

No expert on the drugs, but they do seem promising after reading all the PR's---of course management always skews to the positive

I think at this price there isn't much risk in this stock and if anyone has taken a look at that chart, it is basing in a range so narrow that it's about to break HUGE one way or the other. It has a massive basing pattern within a few cent range and is oversold. Given it's trading at about 1/2 cash position with fully funded upcoming trials, this should break to the upside soon. That is, if the drugs have any promise at all.

GLTAL

[sebirem]

noch jemand dabei?Immer noch auf meiner Watchlist.

CEO kauft Aktien, wenn das nicht überzeugend ist ;9

[sebirem]

2 fette Pakete gestern und vorgestern!
http://www.nasdaq.com/symbol/anx/sec-filings

manchmal ganz gut, dass noch keiner von dieser Perle weiß!!!

Book/sh 1.63
Cash/sh 2.60

"We are pleased to begin 2012 with a strong cash position of over $50 million, which will be used to fund our planned phase 3 study of ANX-188 in patients with sickle cell disease," stated Brian M. Culley, Chief Executive Officer of ADVENTRX."

Hier die PRESS RELEASE der HP von Adventrx.
http://ir.adventrx.com/phoenix.zhtml?c=75414&p=irol-news&nyo…

Hoffe die bringen die Studie endlich zu Ende und erhalten die Zulassung!
Desweiteren "buyout" möglich!

ALLEN VIEL GLÜCK!

[Tommi33]

Antwort auf Beitrag Nr.: 42.916.506 von sebirem am 16.03.12 21:06:06

Ich bin noch da und geniesse die Ruhe hier im Thread, bei Xoma fangen sie schon wieder an zu kreiseln.

LG Tommi

[kunokuhn]

Antwort auf Beitrag Nr.: 42.916.844 von Tommi33 am 16.03.12 22:48:13

bin auch noch dabei
hab aber bei 1,40 € gekauft

[sebirem]

Antwort auf Beitrag Nr.: 42.916.506 von sebirem am 16.03.12 21:06:06

sorry, die Angaben müssen korrigiert werden. Am 16.03 waren diese aber noch aktuell bzw. richtig . na ja...

es muss lauten:
Book/sh 1.19
Cash/sh 0.80

aber selbst das ist noch bemerkenswert

@kunokuhn

Einstiegskurs aus heutiger Sicht nicht optimal, weiss nicht wie hoch dein Einsatz war. Letzlich egal, wenn die Rakete startet

[Tommi33]

ADVENTRX Announces Manufacturing Agreement With Patheon to Manufacture ANX-188 Drug Product

SAN DIEGO, June 26, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that is has entered into a multi-year agreement with Patheon Inc. under which Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the phase 3 study of ANX-188 that ADVENTRX plans to initiate this year.

"This agreement is another step toward initiating the phase 3 study of ANX-188 in patients with sickle cell disease," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "Patheon is a global contract manufacturer that serves more than 300 customers, including many of the world's largest pharmaceutical and biotechnology companies. I am confident in their manufacturing expertise, experienced staff and world-class facilities and pleased to partner with them for the manufacture of ANX-188 clinical trial material."

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on developing proprietary product candidates. The Company's lead product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease. More information can be found on the Company's web site at http://www.adventrx.com/.

[Wohnwunsch]

Lief am Freitag in den USA sehr gut mit einem dicken PLUS 17% aus dem Handel

[Tommi33]

Antwort auf Beitrag Nr.: 43.363.876 von Wohnwunsch am 08.07.12 12:39:18

Das kann alles oder nix bedeuten, ich hab jedenfalls keine News gefunden. Im Moment laufen meine Bios eh alle wie am Schnürchen gezogen gen Norden von daher hoffe ich mal das es weitergeht, ist ja auch noch ein recht herzhaftes dickes Minus.

LG Tommi

[Wohnwunsch]

Antwort auf Beitrag Nr.: 43.364.475 von Tommi33 am 08.07.12 20:36:46

Das kommt drauf an wo man eingestiegen ist.......

Im Vergleich zu anderen Biotechs hat sie allerdings sehr schlecht performt


Ich bin allerdings noch skeptisch bei dieser Aktie

[Tommi33]

Antwort auf Beitrag Nr.: 43.364.488 von Wohnwunsch am 08.07.12 20:41:14

Das ist wohl wahr, bin etwas weiter oben rein und dann kam auch noch eine Reversesplit und es ging noch weiter runter plus schlechte Ergebnisse. Da half auch kein "Strich drunter und weg damit" mehr. Aber ich bin ja ein geduldiger Mensch und nur realisierte Verluste sind richtige Verluste und wenns nu wieder rauf geht auch schön.

Würde nur gern wissen was jetzt wieder im Busch ist

Tommi

[Wohnwunsch]

Antwort auf Beitrag Nr.: 43.364.488 von Wohnwunsch am 08.07.12 20:41:14

Vielleicht heisst es jetzt Lemminge anfüttern ?

Oder steht wirklich ne POSitive News an ?

[Tommi33]

ADVENTRX Announces Appointment Of Chief Medical Officer

SAN DIEGO, Aug. 14, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Santosh J. Vetticaden, M.D., Ph.D., will join the Company as Chief Medical Officer and Senior Vice President.

Dr. Vetticaden has more than 25 years of experience in drug development and medicine. His experience spans a variety of therapeutic areas, including anticoagulation, hemophilia, anti-infectives and rheumatology/inflammation. He has directed and managed the clinical development of both large and small molecules, from protocol design to execution of multi-center, global clinical trials.

Dr. Vetticaden has held several senior level positions leading drug development across phase 1 through phase 4 trials at biotech and large pharmaceutical companies. Most recently, he served as Senior Vice President and Chief Medical and Development Officer at Cubist Pharmaceuticals, Inc., where his tenure was highlighted by successful phase 2 trials and advancing multiple drugs into phase 3. At Cubist, he also played a significant role in the development and execution of new business strategy that resulted in significant product pipeline expansion. Prior to joining Cubist, Dr. Vetticaden was Senior Vice President and Chief Medical Officer at Maxygen, Inc., where he had responsibilities and oversight for clinical development and regulatory affairs for all of the company's development programs, including Maxy-VIIa, which he progressed from the non-clinical stage through a phase 1 study in hemophilia, resulting in its outlicense to Bayer. Before Maxygen, he held senior roles in drug development at Scios, Inc., a subsidiary of Johnson & Johnson, Aventis Pharmaceuticals (now Sanofi) and the Whitehall-Robins Healthcare division of American Home Products Corporation (now Pfizer). Dr. Vetticaden has a Ph.D. in the areas of pharmacokinetics and pharmacodynamics from Virginia Commonwealth University; a M.D from the University of Maryland and completed a residency in internal medicine at the Baylor College of Medicine.

"I have been closely involved in the development and lifecycle management of several transformative products, including Lovenox®, Cubicin®, Xarelto®, and Natrecor®, and I look forward to playing a key role in successful development of ANX-188, which has the potential to treat many serious and life-threatening diseases and conditions," said Dr. Vetticaden. "With the phase 3 study in sickle cell disease anticipated to begin this year, joining ADVENTRX is an opportunity to have a potentially transformational impact in the treatment of diseases and conditions associated with microvascular dysfunction."

"Dr. Vetticaden brings to ADVENTRX decades of drug development and clinical experience as well as valuable clinical pharmacology and translational expertise," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "He has a proven track record of advancing innovative therapies through all stages of the product lifecycle and is a welcome addition to our senior management team as we advance ANX-188 into a phase 3 study."

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

[Wohnwunsch]

Soooo schlecht sieht es doch hier überhaupt nicht aus.

Vielleicht können wir die nächsten Tage noch schöne Gewinne
einfahren

[Tommi33]

ADVENTRX Engages Theradex Systems, Inc. to Manage Phase 3 Clinical Study of ANX-188

SAN DIEGO, Oct. 2, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has engaged Theradex® Systems, Inc., a contract research organization with 30 years of experience, to manage the Company's upcoming phase 3 study of ANX-188 (purified poloxamer 188) in sickle cell disease.

"The engagement of Theradex is one of the final steps before initiating our phase 3 study of ANX-188 in patients with sickle cell disease experiencing vaso-occlusive crisis," said Brian M. Culley, Chief Executive Officer of ADVENTRX. "We selected Theradex based on its extensive experience in the management and oversight of clinical trials, which includes studies in patients with sickle cell disease and a 29-year collaboration with the National Cancer Institute in the United States. We are confident in Theradex's ability to assist us in executing a high-quality, efficient phase 3 study of ANX-188."

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

[Tommi33]

ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188
-Conference Call Scheduled for Today at 4:30 p.m. (ET)/1:30 p.m. (PT)

SAN DIEGO, Oct. 25, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today provided details regarding the phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease that it plans to initiate this quarter. The Company will host a conference call today at 4:30 p.m. Eastern Time, 1:30 p.m. Pacific Time (access information below) to discuss the study.

The study will be a randomized, double-blind, two-arm, placebo-controlled study conducted at approximately 40 sites primarily in the U.S. The primary objective will be to demonstrate that ANX-188 reduces the duration of vaso-occlusive crisis in patients with sickle cell disease. The duration of vaso-occlusive crisis will be measured from the time a subject is randomized to the time at which the subject receives the last dose of parenteral opioid analgesic for the treatment of vaso-occlusive crisis prior to hospital discharge. A total of 388 subjects ages 8 to 17 who have sickle cell disease and are experiencing acute pain typical of vaso-occlusive crisis will be enrolled. Using a two-sided alpha of 0.05, the study has approximately 90% power to detect a 16-hour difference between treatment arms. Secondary endpoints will compare re-hospitalization rate (for vaso-occlusive crisis) within 14 days of initial discharge from the hospital and the occurrence of acute chest syndrome within 120 hours of randomization.

"Following an iterative and collaborative dialog with the FDA, and with valuable input from physicians who treat sickle cell patients, we are pleased to have finalized our phase 3 study protocol. Consistent with our plans when we acquired ANX-188, the study will focus on children. In a post-hoc analysis of a prior phase 3 study, ANX-188 demonstrated a statistically significant reduction in the duration of crisis in a subgroup of younger patients. With the improvements we have incorporated into the upcoming study, we believe ANX-188 can improve on the treatment effect that previously was observed and potentially provide a new treatment option for this debilitating and life-threatening condition, for which there are no approved therapies," said Brian M. Culley, Chief Executive Officer of ADVENTRX.

Conference Call Information
Interested parties may access the conference call by dialing [phone] from the U.S. and [phone] from outside the U.S. and should request the ADVENTRX Pharmaceuticals, Inc. Call. The webcast will be available live via the Internet by accessing the Investors section of ADVENTRX's website at http://ir.adventrx.com. Replays of the webcast will be available on the Company's website for 30 days and a phone replay will be available through November 1, 2012 by dialing [phone] from the U.S. and [phone] from outside the U.S. and entering conference reference number 10019681.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

[Tommi33]

ADVENTRX Reports Third Quarter 2012 Financial Results

SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reported financial results for the quarter ended September 30, 2012.

"With a strong cash position of approximately $40 million, we are well positioned to start our phase 3 study of ANX-188 in sickle cell disease," stated Brian M. Culley, Chief Executive Officer of ADVENTRX. "We are pleased that we have finalized the protocol and completed the majority of our manufacturing activities that will enable us to start the study by the end of 2012," Mr. Culley continued.

Third Quarter 2012 Operating Results

ADVENTRX's net loss for the third quarter of 2012 was $3.2 million, or $0.07 per share (basic and diluted), compared to a net loss of $3.5 million, or $0.13 per share (basic and diluted), for the same period in 2011.

Research and development (R&D) expenses for the third quarter of 2012 were $1.7 million, a decrease of $0.4 million, or 19%, compared to $2.1 million for the same period in 2011. The net decrease was primarily due to a $0.8 million decrease in external nonclinical study fees and expenses, which was offset by increases of $0.3 million in personnel costs and $0.1 million in external clinical study fees and expenses. The decrease in external nonclinical study fees and expenses resulted primarily from decreases in research-related manufacturing expenses of $1.1 million for ExelbineTM and $0.2 million for ANX-514. The increase in personnel costs was primarily related to increased headcount, including relocation and recruitment costs for our new Chief Medical Officer.

Selling, general and administrative (SG&A) expenses for the third quarter of 2012 were $1.8 million, a decrease of $0.2 million, or 8%, compared to $2.0 million for the same period in 2011. The decrease resulted primarily from a decrease in consulting fees and legal expenses due to cost-savings realized by discontinuation of commercial-readiness activities related to Exelbine.

Transaction-related expenses for the third quarter of 2012 were ($0.3) million compared to ($0.5) million for the same period in 2011. We recognized transaction-related expenses for the three months ended September 30, 2012 and 2011 due to changes in the fair values at September 30, 2012 and 2011 relative to June 30, 2012 and 2011, respectively, of the contingent asset and contingent liability related to the consideration of our acquisition of SynthRx. The net $0.3 million reduction to transaction-related expenses was primarily due to the increase in our stock price at September 30, 2012 relative to June 30, 2012.

Year-to-Date Operating Results

ADVENTRX's net loss for the nine months ended September 30, 2012 was $11.6 million, or $0.24 per share (basic and diluted), compared to a net loss of $10.9 million, or $0.43 per share (basic and diluted), for the same period in 2011.

R&D expenses for the nine months ended September 30, 2012 were $6.0 million, an increase of $2.0 million, or 49%, compared to $4.0 million for the same period in 2011. The increase was primarily due to a $1.0 million increase in personnel costs, a $0.7 million increase in external nonclinical study fees and expenses and a $0.3 million increase in external clinical study fees and expenses. The increase in personnel costs was primarily related to increased headcount. The increase in external nonclinical study fees and expenses was primarily related to increases in research-related manufacturing expenses of $1.9 million for ANX-188 and $1.0 million for ANX-514, offset by a $2.2 million decrease in research-related manufacturing expenses related to Exelbine.

SG&A expenses for the nine months ended September 30, 2012 were $5.7 million, an increase of $0.3 million, or 7%, compared to $5.4 million for the same period in 2011. The increase resulted primarily from a $0.6 million increase in personnel costs, mainly due to increased headcount, and a $0.5 million increase in share-based compensation expense, offset by a $0.8 million decrease in consulting fees and legal expenses.

Transaction-related expenses for the nine months ended September 30, 2012 were ($0.2) million compared to $1.5 million for the same period in 2011. We recognized transaction-related expenses for the nine months ended September 30, 2012 due to changes in the fair values at September 30, 2012 relative to December 31, 2011 of the contingent asset and contingent liability related to the consideration for our acquisition of SynthRx. The net $0.2 million reduction to transaction-related expenses was primarily due to the increase in our stock price at September 30, 2012 relative to December 31, 2011. Transaction-related expenses for the nine months ended September 30, 2011 consisted of $1.8 million related to legal, accounting, financial and business development advisory fees associated with the evaluation of potential acquisition targets, including SynthRx, and a $0.3 million reduction related to changes in the fair value of contingent consideration related to the SynthRx acquisition.

Balance Sheet Highlights

As of September 30, 2012, the Company had cash, cash equivalents and short-term investments totaling $39.9 million. Stockholders' equity amounted to $46.3 million as of September 30, 2012.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at

www.adventrx.com.

[Tommi33]

ADVENTRX To Initiate Phase 3 Study Of ANX-188
- Study Title: EPIC (Evaluation of Purified poloxamer In Children in crisis)
- Multiple IRB approvals and clinical site agreements in place

SAN DIEGO, Dec. 19, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that ANX-188 drug product for use in the phase 3 clinical study of ANX-188 (purified poloxamer 188), manufactured using the Company's proprietary purification process, has passed quality control (QC) release specifications at Patheon, the Company's contract manufacturer, and currently is in the quality assurance (QA) release process. The study has been approved by multiple institutional review boards (IRB) and initiation of the study is expected in approximately six weeks.

Santosh Vetticaden, Chief Medical Officer, said: "Our clinical operations team has achieved numerous milestones over the past several months that will allow us to initiate the EPIC study as early as next month. We have multiple IRB approvals, multiple clinical trial agreements with study sites, and we have assembled a top-flight data safety monitoring board. Last week, we held our first investigators' meeting, and I was impressed by the level of enthusiasm for the study that was expressed by leaders in the sickle cell disease medical community."

Brian M. Culley, Chief Executive Officer, said: "We were expecting to initiate the study prior to year-end, but unforeseen delays at one of our vendors will push trial initiation into early next year. However, this upfront delay means we will have more sites open at study initiation and the delay will not extend the overall study timeline. Our focus now is on releasing drug product and shipping it to our contract facility on the East Coast, where it will be labeled and distributed to clinical sites, all of which we expect to take place over the next few weeks. In parallel, we continue to qualify and open additional study sites."

Mr. Culley continued: "Looking ahead, we are preparing to initiate a thorough QT study of ANX-188 and announce our plans to develop ANX-188 in an indication outside of sickle cell disease, which will further increase the commercial potential of, and partnering interest in, this important investigational drug."

http://www.adventrx.com/

[Wohnwunsch]

Was ist mit dieser Aktie heute los, warum steigt sie plötzlich so stark ?

[Tommi33]

ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188

SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that it has initiated patient recruitment in its pivotal phase 3 clinical study of ANX-188 (purified poloxamer 188) in sickle cell disease.

Santosh Vetticaden, Chief Medical Officer, said: "The substantial effort that went into the design of this study is reflected by the enthusiasm that we have heard from thought leaders and clinical sites who wish to participate. In particular, the study's primary endpoint, in which crisis resolution is based on the time at which subjects receive their last dose of parenteral opioid analgesic, provides a level of objectivity, specificity and reliability that is unattainable with endpoints based on pain scores or time to hospital discharge. We believe that ANX-188 has the potential to be the first FDA-approved product for sickle cell disease vaso-occlusive crisis in fifteen years."

Brian M. Culley, Chief Executive Officer, said: "ADVENTRX now is the only company with a new molecular entity in phase 3 for the treatment of sickle cell disease, a disease with significant unmet needs and which has been experiencing unprecedented levels of interest from both strategic partners and financial investors. We believe ANX-188 is well-positioned for regulatory and commercial success due in part to:

Orphan drug designation by FDA for sickle cell disease, which is expected to provide ANX-188 with seven years of post-approval exclusivity in the U.S.;
Fast track designation by FDA for sickle cell disease, which makes ANX-188 eligible for accelerated approval and rolling review and likely to be considered appropriate for priority review;
A competitive landscape in which there are no drugs approved to treat an on-going vaso-occlusive crisis;
The potential to receive a priority review voucher under the rare pediatric disease incentive program, which voucher entitles the holder to priority (6-month) review of a new drug or biologics license application and which voucher can be sold prior to being used. This year, we plan to seek designation of ANX-188 as a drug for a rare pediatric disease."

About EPIC (Evaluation of Purified 188 In Crisis)

The EPIC study is a randomized, double-blind, two-arm, placebo-controlled study that will be conducted at approximately 40 sites, primarily in the U.S. The primary objective is to demonstrate that ANX-188 reduces the duration of vaso-occlusive crisis in patients with sickle cell disease. The duration of vaso-occlusive crisis will be measured from the time a subject is randomized to the time at which the subject receives the last dose of parenteral opioid analgesic for the treatment of vaso-occlusive crisis prior to hospital discharge. A total of 388 subjects ages 8 to 17 who have sickle cell disease and are experiencing acute pain typical of vaso-occlusive crisis will be enrolled. Using a two-sided alpha of 0.05, the study has approximately 90% power to detect a 16-hour difference between treatment arms. Secondary endpoints will compare re-hospitalization rate (for vaso-occlusive crisis) within 14 days of initial discharge from the hospital and the occurrence of acute chest syndrome within 120 hours of randomization.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a biopharmaceutical company developing proprietary product candidates to treat various diseases and conditions. The Company's lead product candidate, ANX-188, has potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in a wide range of serious and life-threatening diseases and conditions. The Company initially is developing ANX-188 as a treatment for complications arising from sickle cell disease. More information can be found on the Company's web site at www.adventrx.com.

[Tommi33]

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications
- Platform includes over 100 pharmacology studies, 15 clinical studies and 2,500 patient exposures
- ANX-188 phase 2-ready in multiple indications outside of sickle cell disease

SAN DIEGO, Feb. 26, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today reviewed the platform of data and know-how that supports development of ANX-188 in multiple indications, including those outside of sickle cell disease. This platform has been derived from over 100 pharmacology studies, more than 15 clinical studies in multiple indications in which over 2,500 subjects have been exposed to both purified and non-purified poloxamer 188, and over two decades of experience manufacturing and purifying poloxamers.

Brian M. Culley, Chief Executive Officer, said: "Since acquiring SynthRx, we have come to appreciate the extent of the data supporting the development of ANX-188 not just in sickle cell disease, but in any indication where improving microcirculatory insufficiency is central to improving clinical outcomes. The breadth and depth of these data can be characterized as a 'platform,' which we refer to as the Molecular Adhesion and Sealant Technology, or MAST, platform. We plan to leverage the knowledge and know-how that is the MAST platform to advance ANX-188 in multiple indications, and will announce development plans outside of sickle cell disease later this quarter."

R. Martin Emanuele, Ph.D, Senior Vice President, Development, said: "In addition to initiating EPIC, our pivotal phase 3 study in sickle cell disease, we have analyzed the impressive body of data that supports development of ANX-188 in a broader range of diseases and conditions. ANX-188 adheres specifically to hydrophobic surfaces characteristic of damaged cells in the circulation, effectively 'sealing' the damaged area and, as a result, minimizing or preventing other hydrophobic adhesive interactions and providing time for natural repair mechanisms to restore normal functioning. Meanwhile, because pathological hydrophobic domains are not characteristically present in a healthy circulation, ANX-188 has no clinically significant activity in healthy circulatory tissue. While this mechanism specifically targets hydrophobic domains, these domains can be widespread in sick or injured patients. This 'broadly targeted' activity gives ANX-188 potential to address multiple pathophysiological processes in complex indications relative to drugs based on specific receptor/ligand interactions."

Santosh Vetticaden, Chief Medical Officer, said: "Proof-of-concept in experimental models has been demonstrated with the active ingredient in ANX-188 in a wide range of diseases, such as arterial disease, stroke, shock and heart failure. As we advance ANX-188 into new indications, we intend to leverage already completed IND-enabling toxicology studies, phase 1 safety studies and the other activities that consume so much time and money in drug development. With clinical trial material already in-hand, we expect to move ANX-188 directly into phase 2 studies and generate clinical proof-of-concept data in new indications in relatively short time frames with relatively modest investment."

http://www.adventrx.com/investors/news/?releaseid=1789251

[Tommi33]

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"
Name and ticker symbol changes effective March 11, 2013

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that, effective March 11, 2013, its corporate name will be "Mast Therapeutics, Inc."

Brian M. Culley, Chief Executive Officer, said: "The new corporate identity we announce today is the final step in a transformational process through which we have changed fundamentally this company's priorities, personnel and business focus. In 2009, substantially all of our business operations were suspended and we had 2 employees. Since then, we have appointed a new management team and Board of Directors, acquired ANX-188, the most clinically advanced new drug in sickle cell disease, initiated a pivotal phase 3 study in this orphan indication, and announced our plans to initiate a phase 2 study of ANX-188 in acute limb ischemia, a complication of peripheral arterial disease. We no longer are developing reformulated chemotherapeutic products. Our company today is dramatically different from 12 months ago and the 'Adventrx' name no longer reflects our strategic vision."

Mr. Culley continued: "We now have in place the right team, the right programs and the opportunity to bring new therapies to patients with significant unmet needs in multiple therapeutic areas. This week's introduction of the MAST platform and our plans to develop ANX-188 for complications of arterial disease solidify our commitment to this franchise. Our new corporate identity embodies the fundamental changes that have taken place over the past several years and reflects that, in a very fundamental sense, we are a new company."

Details Regarding Name Change from ADVENTRX Pharmaceuticals to "Mast Therapeutics"

The following changes will be effective prior to trading on Monday, March 11, 2013:

The Company's name will be "Mast Therapeutics, Inc.".
The Company's common stock will be traded on the NYSE MKT under the ticker symbol "MSTX" (currently, "ANX").
A new CUSIP number of 576314 108 will be assigned to the Company's common stock and a new CUSIP number of 576314 116 will be assigned to the common stock purchase warrants of the Company that were issued in November 2011.
The Company's website will be available at www.masttherapeutics.com (currently, www.adventrx.com).
The Company's lead product candidate will be referred to as "MST-188" (currently, ANX-188).

Outstanding stock certificates and warrants for shares of the Company's common stock are not affected by the name change; they will continue to be valid and need not be exchanged.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in San Diego, CA. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop ANX-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs. ANX-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).

The Company is recruiting subjects in EPIC, a pivotal phase 3 study of ANX-188 in sickle cell disease. The Company plans to initiate a phase 2 clinical study of ANX-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014. More information can be found on the Company's web site at www.adventrx.com.

[Tommi33]

Adventrx To Develop ANX-188 For Complications Of Arterial Disease
- Seeking orphan drug designation in acute limb ischemia (ALI)
- Phase 2 clinical proof-of-concept in ALI planned for late 2013/early 2014
- CONFERENCE CALL TOMORROW AT 8:30 AM (ET) (details below)

SAN DIEGO, Feb. 28, 2013 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced its plans to develop ANX-188 in complications of arterial disease, initially as an adjunct to thrombolytics in acute limb ischemia (ALI), a complication of peripheral arterial disease. Peripheral arterial disease affects an estimated 8 to 12 million people in the United States.

Arterial disease resulting from atherosclerotic and thromboembolic processes is a common circulatory problem in which plaque-obstructed arteries reduce the flow of blood to tissues. Peripheral arterial disease refers to disease affecting arteries outside the brain and heart and often refers to blockage of arteries in the lower extremities. Ischemic cerebrovascular infarction, or stroke, results from blockage of arteries to the brain, while myocardial infarction, or heart attack, results from blockage of arteries to the heart. Thrombolytic agents, such as tPA (tissue plasminogen activator), commonly referred to as "clot busting" drugs, are used to treat acute complications of peripheral arterial disease, heart attack and stroke.

R. Martin Emanuele, Senior Vice President, Development, said: "Data from experimental models demonstrate the potential for ANX-188, when used alone or in combination with thrombolytics, to improve outcomes for patients with thrombotic arterial disease, whether manifesting as acute limb ischemia, stroke or some other variant. Studies in animals and humans suggest that ANX-188 can shorten time-to-thrombolysis, improve blood flow, delay re-occlusion and reduce reperfusion injury, each of which may improve the effectiveness of existing thrombolytic agents."

Santosh Vetticaden, Chief Medical Officer, said: "We plan to evaluate the potential of ANX-188 in arterial disease initially by evaluating it in acute limb ischemia. Near-term goals include seeking orphan drug designation for ANX-188 in ALI, meeting with FDA to discuss our development plan in ALI and, assuming FDA agrees with the plan, initiating a phase 2, clinical proof-of-concept study in late 2013 or early 2014. Currently, we estimate that third-party costs to conduct this study will be approximately $2 million and that it will take approximately 15 to 18 months to enroll. Ultimately, we plan to leverage the data in ALI to find a partner to develop ANX-188 in larger indications within arterial disease, such as stroke."

Conference Call Information
The Company will hold a conference call tomorrow, Friday, March 1, 2013, at 8:30 a.m. (ET), 5:30 a.m. (PT) to discuss its development plans in acute limb ischemia. Interested parties may access the conference call by dialing [phone] from the U.S. and [phone] from outside the U.S. and should request the ADVENTRX Pharmaceuticals Update Call. The webcast will be available live via the Internet by accessing the Events & Presentations page of Investors section of ADVENTRX's website at http://www.adventrx.com/investors/events/. Replays of the webcast will be available on the Company's website for 30 days and a phone replay will be available through March 6, 2013 by dialing [phone] from the U.S. and [phone] from outside the U.S. and entering conference reference number 10025903.

About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a publicly traded biopharmaceutical company headquartered in San Diego, CA. The Company is leveraging the MAST (Molecular Adhesion and Sealant Technology) platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop ANX-188, its lead product candidate, for serious or life-threatening diseases with significant unmet needs. ANX-188 is a cytoprotective, hemorheologic, anti-inflammatory and anti-thrombotic agent that has potential utility in diseases or conditions characterized by microcirculatory insufficiency (endothelial dysfunction and/or impaired blood flow).

The Company is recruiting subjects in EPIC, a pivotal phase 3 study of ANX-188 in sickle cell disease. The Company plans to initiate a phase 2 clinical study of ANX-188 in acute limb ischemia, a complication of peripheral arterial disease, in late 2013 or early 2014. More information can be found on the Company's web site at www.adventrx.com.